B-MoGen Biotechnologies, Inc. announced today that it has completed its Series A financing with Bio-Techne, Mayo Clinic Ventures and Discovery Capital.

MINNEAPOLIS, MN, UNITED STATES, June 16, 2016 /EINPresswire.com/ -- B-MoGen Biotechnologies Completes Series A Financing
MINNEAPOLIS, June 13, 2016/PRNewswire/ –– B-MoGen Biotechnologies, Inc. announced today that it has successfully completed its Series A financing with Bio-Techne and University of Minnesota’s Discovery Capital Investment Program co-leading the investment round. Additional investors include Mayo Clinic Ventures and Lateral Capital.
B-MoGen is a University of Minnesota spin-off founded by David Largaespada and Branden Moriarity, two faculty members from the Masonic Cancer Center, University of Minnesota who deploy cutting-edge methods for gene editing and gene delivery in the search for novel non-viral techniques that will further advance cellular therapeutics. The startup plans to commercialize these proprietary molecular tools and provide innovative services to drive research and discovery in the new CRISPR age. The explosion of applications in genome editing is fueling new advancements to the basic CRISPR molecular toolkit, and B-MoGen is actively participating in this field with a raft of novel approaches. Additionally, B-MoGen’s exclusive license with Mayo Clinic for mitochondria editing enables precise introduction of deletions into the mitochondrial genome of living cells.
Bio-Techne, a world leader in providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, is excited to engage B-MoGen’s unique expertise to explore the use of new gene editing technologies to continue improving the production, bioactivity, and quality of their market-leading protein and antibody reagents.
Dr. Fernando Bazan, Chief Technology Officer for Bio-Techne, commented that “B-MoGen is a terrific investment in an emerging field of novel molecular and discovery tools that not only drives new science at a dizzying pace, but also provides a strong technological foundation for Bio-Techne to explore new generations of high-quality protein, antibody and cellular reagents, build innovative assays and instruments, and continue strongly as the leader in this life science field.”
The University of Minnesota Discovery Capital program supports early-stage companies like B-MoGen that are commercializing University technology. The program aims to curb the time it takes to bring promising innovations to market.
Jay Schrankler, executive director of the University of Minnesota Office for Technology Commercialization, noted that “B-MoGen, driven by talented University researchers and cutting-edge technology, holds enormous potential and was a natural fit for a Discovery Capital investment. We are excited to envision the many ways the startup’s leadership will channel their expertise and passion to develop tools that can help improve our society’s health and wellbeing.”
Jeff Liter, Chief Executive Officer of B-MoGen Biotechnologies, added, "We are pleased and excited to have such a broad base of support in our Series A financing and to be working with Bio-Techne in deploying our gene editing technology in an innovative effort to improve certain Bio-Techne products. Moreover, B-MoGen technology has tremendous therapeutic potential as we optimize our methods for non-viral gene delivery into primary cells. Finally our work with mitochondrial editing is showing great promise for new applications”.
*********************************
B-MoGen Biotechnologies, Inc. is a genome editing company that was born out of a necessity for better biological research tools. We have developed innovative methods that employ cutting edge and time-tested genome editing technologies to study human disease and genetics. We offer our unique gene editing solutions for antibody validation, human disease research, gene transfer and mitochondrial DNA editing. Please visit us at www.bmogen.com.
Contact: Kristin Taylor Geisler, CFO
Kristin@bmogen.com
612-656-4576

Jeff Liter
B-MoGen Biotechnologies
612-309-7653
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.